immunotherapy malaria hemorragic fever geovax vaccines zika aids/hiv hbv lassa lasv

GeoVax Labs, Inc. (GOVX-OTC) Announces Publication of HIV Vaccines Review

1 Minute Read


GeoVax Labs, Inc. announced today the publication of a manuscript entitled “HIV/AIDS Vaccines: 2018,” authored by Harriet L. Robinson, PhD, GeoVax’s Director of HIV Vaccines and Chief Scientific Officer Emeritus. The paper is published in the peer-reviewed journal Clinical Pharmacology & Therapeutics, a journal of the American Society for Clinical Pharmacology & Therapeutics (ASCPT), and can be viewed at Dr. Robinson provides a comprehensive review of progress toward development of an HIV/AIDS vaccine in the article, including key challenges and lessons learned from completed efficacy trials. 

Despite development of effective antiretroviral therapies (ART), only 49% and 48% of people living with HIV in the U.S. and worldwide, respectively, have drug-controlled infections. Patients without drug-controlled infections develop AIDS and spread the infection. This indicates that for eliminating HIV, there is a need for an effective vaccine to be added to the arsenal of ART. Thus, only with a demonstrated effective HIV/AIDS vaccine can people worldwide avoid the infection, ongoing health risks, and societal impact resulting from this disease. GeoVax is a leader in developing a vaccine for the clade B subtype of HIV prevalent in the Western Hemisphere, Europe, and Japan. The Company's vaccine, GOVX-B11, is currently progressing in human clinical trials with the sponsorship of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).”

GeoVax's development programs are focused on vaccines against HIV as well as Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa), and malaria. GeoVax also is evaluating the use of its MVA-VLP platform in cancer immunotherapy and for therapeutic use in chronic Hepatitis B infections. .

For more information on GeoVax, please refer to our most recent Quarterly Update ( dated August 14, 2018, as well as our Executive Informational Overview (EIO), issued on June 15, 2017 and available for download below.

Download GeoVax Report 



Visit our Corporate Profile and Key Points pages

for the latest research on GeoVax Labs, Inc.